Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): An open-label study

ADHD Attention Deficit and Hyperactivity Disorders

Volumn 3, Issue 4, 2011, Pages 319-326

  Gabriel, Adel ^a   Violato, Claudio ^b  

^a CALGARY HEALTH REGION   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

ADHD; Atomoxetine; GA comorbidity

Indexed keywords

ATOMOXETINE; CITALOPRAM; ESCITALOPRAM; FLUVOXAMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADJUVANT THERAPY; ADULT; AGED; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DISABILITY SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY EYE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HEART PALPITATION; HUMAN; IRRITABILITY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULSE RATE; RHINORRHEA; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; WEIGHT CHANGE; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; BODY WEIGHT; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 81455135092     PISSN: 18666116     EISSN: 18666647     Source Type: Journal    
DOI: 10.1007/s12402-011-0063-1     Document Type: Article

References (42)

1. Adler LA, Reingold LS, Morrill MS, Wilens TE (2006a) Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 8(5): 409-415.
2. Adler L, Sutton V, Moore R, Dietrich A, Reimherr F, Sangal R, Saylor K, Secnik K, Kelsey D, Allen A (2006b) Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 26(6): 648-652.
3. Adler L, Spencer T, Farone S, Kessler R, Howes M, Beiderman J, Secnik C (2006c) Validity of pilot adult ADHD self report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry 18(3): 145-148.
4. Adler L, Spencer T, Williams D, Moore R, Michelson D (2008a) Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 12(3): 248-253.
5. Adler L, Spencer T, Levine L, Ramsey J, Tamura R, Kelsey D, Ball S, Allen AJ, Biederman J (2008b) Functional outcomes in the treatment of adults with ADHD. J Atten Disord 11(6): 720-727.
6. Adler L, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz P, Williams D, Kelsey D (2009) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 29(1): 44-50.
7. Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson J, den Boer J, Fineberg N, Knapp M, Scott J, Wittchen H (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19: 567-596.
8. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67(4): 524-540.
9. Brown R, Amler R, Freeman W (2005) Treatment of attention deficit hyperactivity disorder: overview of evidence. Paediatrics 115: 749-757.
10. CADDRA: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (2008) Canadian ADHD practice guidelines. CADDRA, Toronto.
11. Christman AK, Fermo JD, Markowitz JS (2004) Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 24(8): 1020-1036.
12. Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A (2009) Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 23(9): 739-753. doi: 10. 2165/11314350-000000000-00000.
13. Durell T, Adler L, Leibowitz M, Rubin R, Qiao M, Hollandbeck M, Deldar A, Glaser P, Kronenberger W (2010) An 8-week, open label extension period study of atomoxetine in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. J ADHD Relat Disord 3: 36-52.
14. Gabriel A (2010) The mixed amphetamine salt extended release (Adderall XR, MAX-XR) as an adjunctive to SSRIs or SNRIs in the treatment of adult patients with comorbid partially responsive generalized anxiety: an open label study. ADHD Atten Def Hyp Disord 2010(2): 87-92.
15. Gadde K, Yonish G, Wagner HR, Foust M, Allison D (2006) Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond) 30(7): 1138-1142.
16. Garnock-Jones KP, Keating GM (2009) Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11(3): 203-226. doi: 10. 2165/00148581-200911030-00005.
17. Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, Bakken R, Paczkowski M, Kelsey D, Sumner C (2007) Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 46(9): 1119-1127.
18. Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Rockville.
19. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
20. Henning E, Turk C, Mennin D, Fresco D, Heimberg R (2007) Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 24: 342-349.
21. Kessler R, Brandenburg N, Lane M, Roy-Byrne P, Stang P, Stein D, Wittchen H (2005) Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 35: 1073-1082.
22. Kessler R, Adler L, Barkley R, Biederman J, Conners C, Demler O, Faraone S, Greenhill L, Howes M, Secnik K, Spencer T, Ustun T, Walters E, Zaslavsky A (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163(4): 716-723.
23. Kratochvil C, Vaughan B, Harrington M, Burke W (2003) Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 4: 1165-1174.
24. Kratochvil C, Newcorn J, Arnold L, Duesenberg D, Emslie G, Quintana H, Sarkis E, Wagner KD, Gao H, Michelson D, Biederman J (2005) Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44(9): 915-924.
25. Matza LS, Johnston JA, Faries DE, Malley KG, Brod M (2007) Responsiveness of the adult attention-deficit/hyperactivity disorder quality of life scale (AAQoL). Qual Life Res 16(9): 1511-1520 (Epub 2007 Sep 12).
26. McGough J, Smalley S, McCracken J, Yang M, Del'Homme M, Lynn D, Loo S (2005) Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 162: 1621-1627.
27. McIntyre RS, Konarski JZ, Mancini DA, Fulton KA, Parikh SV, Grigoriadis S, Grupp LA, Bakish D, Filteau MJ, Gorman C, Nemeroff CB, Kennedy SH (2005) Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ 173(11): 1327-1334.
28. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53: 112-120.
29. Ravindran L, Kim D, Letamendi A, Stein M (2009) A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 29(6): 561-564.
30. Ruscio A, Chiu W, Roy-Byrne P, Stang P, Stein D, Wittchen H, Kessler R (2007) Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 21: 662-676.
31. Schweizer E (1995) Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Psychiatr Clin North Am 18: 843-857.
32. Scott N, Ripperger-Suhler J, Rajab M, Kjar D (2010) Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 20(3): 197.
33. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-international neuropsychiatric interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33.
34. Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64: 205-222.
35. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155(5): 693-695.
36. Spencer T, Faraone S, Michelson D, Adler L, Reimherr F, Glatt S, Biederman J (2006) Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 67(3): 415-420.
37. Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28(11): 1892-1908.
38. van Brunt D, Johnston J, Ye W, Pohl G, O'Hara N (2006) Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm 12(3): 230-238.
39. Vaughan B, Fegert J, Kratochvil CJ (2009) Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 10(4): 669-676.
40. Wade A, Despiegel N, Heldbo Reines E (2006) Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 18: 83-89.
41. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26(10): 729-740.
42. Wilens T, Biederman J, Faraone S, Martelon M, Westerberg D, Spencer T (2009) Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry 70: 1557-1562.